<DOC>
	<DOCNO>NCT00117533</DOCNO>
	<brief_summary>The treatment choice chronic hepatitis D uncertain . The investigator hypothesize pegylated interferon ( IFN ) alfa-2b combination ribavirin ( RBV ) may effective treatment chronic hepatitis D patient also infect hepatitis B virus ( HBV ) . The purpose study test hypothesis . The investigator use pegylated IFN alfa-2b combination RBV treatment patient dual chronic hepatitis D virus ( HDV ) HBV infection . A 24-week course combination therapy pegylated IFN+RBV use .</brief_summary>
	<brief_title>Pegylated Interferon Alfa-2b Plus Ribavirin Chronic Hepatitis B Delta</brief_title>
	<detailed_description>Recombinant IFN alfa possess anti-viral immunomodulatory effect show effective chronic hepatitis B [ Davis et al . 1989 ; Bisceclie et al , 1989 ] . Interferon alfa also one approve treatment chronic hepatitis B . Administration IFN alfa-2b adult lead disappearance HBV DNA without HBeAg seroconversion 30-50 % patient , two three time rate yearly spontaneous HBeAg seroconversion ( 10-15 % ) . Normalization serum ALT occur case . Loss HBsAg observe 10-15 % Caucasian patient prolong post-treatment follow-up period . Recently , study suggest high proportion patient receive pegylated IFN could achieve HBeAg seroconversion control HBV replication [ Marcellin et al , 2004 ; Lau et al , 2004 ; Jensen et al , 2004 ] . RBV another antiviral nucleotide analogue adverse effect [ Sidwell et al , 1972 ; Patterson et al , 1990 ] . RBV alone modestly inhibit HDV HBV replication [ Choi et al , 1989 ] . The beneficial effect combine IFN plus RBV treatment chronic hepatitis B also show previous study [ Cotonat et al , 2000 ] . Why RBV greatly enhance treatment efficacy clear . It show ribavirin could inhibit interleukin-4 , inhibitor cytotoxic T lymphocyte activity , preserve interleukin-2 gamma IFN activity . Other study reveal enhanced efficacy associate HBV- virus-specific type 1 cytokine-mediated T helper cell response [ Cramp et al , 2000 ; Tam et al , 1999 ; Hultgren et al , 1998 ; Fang et al , 2002 ; Fang et al , 2000 ; Rico et al , 2001 ] . Thus , combination therapy may augment virus-specific cytotoxic T lymphocytes non-specific immune response , effectively shift immune response potent antiviral type 1 T-helper profile [ Hultgren et al , 1998 ] . HDV , like HCV , RNA virus . Indeed , RBV also show active HDV replication cell culture [ Choi et al , 1989 ] . The investigator therefore hypothesize pegylated IFN alfa-2b combination RBV yield efficacy chronic hepatitis D patient dually infected HBV . The purpose protocol test hypothesis . A previous study find high-dose IFN may improve efficacy chronic hepatitis D patient . Another pilot study use IFN alfa plus RBV also demonstrate seroclearance HCV RNA affect HBV coinfection [ Liu et al , 2003 ] . The investigator thus use pegylated IFN alfa-2b combination RBV treatment patient dual chronic HDV HBV infection . The treatment choice chronic hepatitis D clarify till . In proposal , dosage duration combination regimen decide mainly experience treatment chronic hepatitis B chronic hepatitis C. The investigator recent study use ribavirin interferon ( IFN ) combination therapy dual chronic hepatitis B C suggest combine ribavirin 1,200 mg daily 6 month , together 6 million unit ( MU ) IFN-alpha 2a thrice weekly 12 week 3 MU another 12 week effective clearance HCV RNA [ Liu et al , 2003 ] . Twenty-four patient chronic hepatitis seropositive hepatitis B surface antigen antibody HCV receive ribavirin 1,200 mg daily 6 month , together 6 million unit ( MU ) IFN-alpha 2a thrice weekly 12 week 3 MU another 12 week . The serum HCV clearance rate 43 % 24 week posttreatment . The serum ALT normalization rate 43 % 24 week posttreatment . In hepatitis B C dually infect patient , combination IFN ribavirin achieve sustain HCV clearance rate comparable hepatitis C alone . Furthermore , previous study reveal 12-week RBV therapy effective patient chronic hepatitis B [ Kakumu et al , 1993 ] . Therefore , 24-week course combination therapy pegylated IFN+RBV use . Increased RBV dosage consider contributory factor well efficacy treat refractory genotype HCV . For example , recent study suggest use RBV 800 mg daily adequate treat HCV genotype non-1 standard dosage RBV require treat HCV genotype 1 [ NIH 2002 ] . The investigator thus propose use RBV 1000-1200 mg daily accord body weight patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Be positive antiHDV HBsAg 6 month Present elevate serum ALT level least 1.5 time upper limit normal , document two occasion ( least one month apart ) , within six month prior enrollment Be HDV RNA positive PCR ( sensitivity : 103 copies/mL ) [ Yamashiro et al , 2004 ] Be HBV DNA positive PCR Present liver biopsy finding compatible diagnosis chronic liver disease ( liver biopsy need take within 52 week prior enrollment ) Have adequate liver reserve ( define equal well ChildPugh Class A ) Present WBC ≥3000/mm3 , ANC ≥1500/mm3 , platelet ≥80,000/mm3 Be able likely attend regularly treatment followup Give write informed consent Be negative urine pregnancy test ( female childbearing potential ) , document within screen period within 24 hour prior first dose study drug All male patient female partner childbearing age use barrier method contraception All female patient childbearing potential must use two reliable form effective contraception Drug addict history histological evidence alcohol abuse , currently receive prescription may cause hepatotoxicity Have decompensated cirrhosis cod ChildPugh classification ( i.e . history ascites , history bleed esophageal varix , severe portal hypertension , serum albumin &lt; 30 g/l , serum bilirubin &gt; 30 mg/l ) Present WBC &lt; 3000/mm3 , ANC &lt; 1500/mm3 , platelet &lt; 90,000/mm3 Present hemoglobin &lt; 12.0 gm/dl female &lt; 13.0 gm/dl male Have treat immunosuppressive therapy within past six month ( e.g . steroid , azathioprine , cyclophosphamide ) Have renal insufficiency ( serum creatinine &gt; 150 μmol/l ) Have clot abnormality preclude liver biopsy Have evidence serious neurological dysfunction Have obesity diabetes mellitusinduced liver disease Have serological evidence autoimmune chronic liver disease ( e.g . antinuclear antibody titer &gt; 1:320 , and/or smooth muscle antibody titer &gt; 1:160 ) Hemophiliacs Have evidence inheritable disorder haemochromatosis , alpha1antitrypsin deficiency Wilson 's disease Have expose hepatotoxic substance might cause hepatitis Pregnant , lactate practice adequate form birth control , oral contraceptive intrauterine device Seropositive antiHIV antiHCV Have serious psychological psychiatric problem disrupt daily activity Have AFP ( alphafetoprotein ) great 20 ng/ml ; case elevate AFP , abdomen ultrasonography require exclude possibility HCC Have serious heart disease ( coronary heart disease , etc ) Have history asthma drug allergy may lead hypersensitivity ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>chronic hepatitis B ;</keyword>
	<keyword>chronic hepatitis delta ;</keyword>
	<keyword>treatment ;</keyword>
	<keyword>pegylated interferon alfa-2b ;</keyword>
	<keyword>ribavirin</keyword>
</DOC>